A carregar...
Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment
Classic Hodgkin lymphoma (cHL) stands out as success story in the field of medical oncology, with multiagent chemotherapy with or without radiation leading to durable remission for most patients. Large-scale clinical trials during the past 40 years have sought to minimize toxicities while maintainin...
Na minha lista:
| Publicado no: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6913455/ https://ncbi.nlm.nih.gov/pubmed/31808838 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2019000030 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|